Malaria vaccine successfully tested in humans


Monday, 27 March, 2017

Malaria vaccine successfully tested in humans

Griffith University researchers have shown that the whole blood-stage malaria parasite vaccine PlasProtecT, tested in collaboration with the Gold Coast University Hospital, is safe and induces an immune response in humans.

The world-first project has been years in the making for Professor Michael Good and Dr Danielle Stanisic, who first began clinical trials in 2013. Dr Stanisic explained that volunteers, who had to attend appointments at Griffith’s Clinical Trials Unit every two days for a month, were administered with inactivated human malaria parasites that prevent them from growing and causing a malaria infection.

Professor Good had so much faith in the vaccine that he was the first person to receive it.

“I wouldn’t ask people to do what I wouldn’t be prepared to do, and we couldn’t do this without the volunteers who give their time to us knowing they are helping further work towards a cure,” he said.

Dr Stanisic explained that the vaccine was initially found to be able to induce cross-species protection in preclinical trials. “We’ve now taken a human version of the vaccine and tested it in volunteers and shown it is safe and induces an immune response,” she said.

“We are the first to put a vaccine like this into humans that has potential to protect against multiple strains and species of malaria.”

The researchers’ next trial will test whether or not the vaccine protects people by immunising volunteers and challenging them with the malaria parasite. They are also seeking to take their project to malaria-endemic countries — a move that will cost them $500,000.

Rotary clubs are now ramping up fundraising efforts for the researchers, with Governor-General Sir Peter Cosgrove today launching the Malaria Vaccine Project. The project has already raised $50,000 and is accepting further donations at https://malariavaccineproject.com/.

Rotary past district governor Graham Jones said Rotary’s work with impregnated nets is helping in all kinds of endemic countries, but an effective vaccine is sorely needed.

“This research could be the gateway to sustainable development of the vaccine and its use in eradicating malaria worldwide,” he said.

Image courtesy of CDC Global under CC BY 2.0

Related News

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...

Archer completes potassium sensing alpha prototype

Quantum technology company Archer Materials Limited has developed an early Biochip prototype...

Farm animals and aquaculture cryopreservation partnership announced

Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd